Back to top

oncology-screening: Archive

Zacks Equity Research

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.

AZNNegative Net Change ENTXNegative Net Change ANVSNegative Net Change ALXONegative Net Change

Zacks Equity Research

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.

LGNDNegative Net Change ANIPNegative Net Change BGNENegative Net Change ANVSNegative Net Change

Zacks Equity Research

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.

AZNNegative Net Change BMYPositive Net Change MRKPositive Net Change LGNDNegative Net Change